Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor

Vascular endothelial growth factor receptor 2 (VEGFR2), a key regulator of tumor angiogenesis, is highly expressed across numerous tumor types and has been an attractive target for anti-cancer therapy. However, clinical application of available VEGFR2 inhibitors has been challenged by limited effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Seong, Strickland, Bill, Finis, Lynda, Kooijman, Jeffrey J., Melis, Janneke J. T. M., Zaman, Guido J. R., Van Tornout, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192158/
https://www.ncbi.nlm.nih.gov/pubmed/37148323
http://dx.doi.org/10.1007/s00280-023-04534-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192158/
https://www.ncbi.nlm.nih.gov/pubmed/37148323
http://dx.doi.org/10.1007/s00280-023-04534-7

Ejemplares similares